Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF.
- Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF.
- Other sites and countries are expected to resume screening and randomization activities progressively over the next weeks.
- Clinical sites located in the United States operating under central IRB have meanwhile resumed screening and randomization activities.
- Inventiva anticipates the last patient first visit for the NATiV3 clinical trial in the first half of 2024.